- Home
- MGNX vs LUCD Comparison
MGNX vs LUCD Comparison
Compare MGNX & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGNX | LUCD |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.6M | 206.0M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MGNX | LUCD |
|---|---|---|
| Price | $4.59 | $1.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $5.00 | $4.13 |
| AVG Volume (30 Days) | 662.0K | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $149,500,000.00 | $4,346,000.00 |
| Revenue This Year | N/A | $115.58 |
| Revenue Next Year | $3.19 | $130.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $1.19 | $0.90 |
| 52 Week High | $4.64 | $1.63 |
Technical Indicators
Market Signals| Indicator | MGNX | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 65.09 | 53.02 |
| Support Level | $1.49 | $1.02 |
| Resistance Level | N/A | $1.12 |
| Average True Range (ATR) | 0.29 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 69.03 | 77.78 |
Price Performance
Historical ComparisonAbout MGNX MacroGenics Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.